Industrial microbiology

Centrient Pharmaceuticals joins Almirall’s growing innovation hub in Barcelona

Retrieved on: 
Tuesday, October 10, 2023

The center serves as a hub where researchers from biotech companies, startups, universities, and other scientific institutions can collaborate fostering an ideal environment for innovation.

Key Points: 
  • The center serves as a hub where researchers from biotech companies, startups, universities, and other scientific institutions can collaborate fostering an ideal environment for innovation.
  • The establishment of an Innovation Laboratory at Almirall's R&D facilities is a strategic milestone for Centrient.
  • Rex Clements, Chief Executive Officer of Centrient Pharmaceuticals, expressed his enthusiasm, stating: "The new Innovation Laboratory is an exhilarating strategic leap for Centrient Pharmaceuticals.
  • Almirall's ultimate goal is to create a pharmaceutical innovation hub where different companies can execute their innovation strategies.

Arriello appoints experienced biotech expert, Kate Coleman, as VP of Quality & Compliance

Retrieved on: 
Wednesday, September 20, 2023

DUBLIN, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Arriello, a leading provider of integrated Regulatory Affairs, Pharmacovigilance and Auditing & QA solutions and services, has announced that industrial microbiology and quality risk management specialist Kate Coleman, will join the company in September as VP of Quality & Compliance. She joins from PharmaLex, where she was Senior Director/Principal Consultant for Quality Management and Compliance and QMC Head of the UK/Ireland region.

Key Points: 
  • DUBLIN, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Arriello , a leading provider of integrated Regulatory Affairs, Pharmacovigilance and Auditing & QA solutions and services, has announced that industrial microbiology and quality risk management specialist Kate Coleman , will join the company in September as VP of Quality & Compliance.
  • She joins from PharmaLex, where she was Senior Director/Principal Consultant for Quality Management and Compliance and QMC Head of the UK/Ireland region.
  • This last accomplishment, gained in 2009, means Kate can act as a Qualified Person (QP) for clients in the EU.
  • Here she will present on the theme of "QRM and Quality - Making sure fear doesn't undermine your QRM programme" - exploring the purpose of Quality Risk Management.

Dr. Ramon Gonzalez Appointed Chief Scientific Officer at MojiaBio

Retrieved on: 
Wednesday, May 24, 2023

SINGAPORE, May 24, 2023 /PRNewswire/ -- MojiaBio, a fast-growing biomanufacturing company specializing in the sustainable production of feed additives and bio-based materials, is pleased to announce the appointment of Dr. Ramon Gonzalez as its Chief Scientific Officer.

Key Points: 
  • SINGAPORE, May 24, 2023 /PRNewswire/ -- MojiaBio, a fast-growing biomanufacturing company specializing in the sustainable production of feed additives and bio-based materials, is pleased to announce the appointment of Dr. Ramon Gonzalez as its Chief Scientific Officer.
  • "We are thrilled to welcome Dr. Gonzalez to MojiaBio," said Dr. Kevin Li, Board Chairperson at MojiaBio.
  • As Chief Scientific Officer, Dr. Gonzalez will lead the company's biology research and development efforts, oversee external collaborations, identify new product opportunities, and drive the overall scientific strategy.
  • Dr. Ramon Gonzalez currently serves as the Chief Scientific Officer at MojiaBio.

bioMérieux Triples Footprint in Philadelphia with 32,000 sq. ft. State-Of-The-Art Predictive Diagnostics Innovation Center

Retrieved on: 
Tuesday, May 16, 2023

PHILADELPHIA, May 16, 2023 /PRNewswire/ -- bioMérieux, a world leader in in vitro diagnostics, has announced the lease signing of a new, 32,000 sq. ft. state-of-the-art molecular innovation center at the Navy Yard in Philadelphia. In addition to supporting legacy molecular solutions that have been supplied to diverse Beverage and Food customers worldwide, the new site will house bioMérieux's rapidly growing xPRO™ Program, as well as the company's Predictive Diagnostics Innovation Center.

Key Points: 
  • ft. state-of-the-art molecular innovation center at the Navy Yard in Philadelphia.
  • In addition to supporting legacy molecular solutions that have been supplied to diverse Beverage and Food customers worldwide, the new site will house bioMérieux's rapidly growing xPRO™ Program, as well as the company's Predictive Diagnostics Innovation Center.
  • "Expansion of bioMérieux's presence in Philadelphia is essential to maintain the pace of innovation and meet the dynamic needs of our global customers," said Ben Pascal, head of xPRO™ at bioMérieux.
  • The xPRO™ Program is the catalyst that offers advanced molecular diagnostics to food quality and safety departments in the Food Industry.

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference

Retrieved on: 
Thursday, November 3, 2022

RAFT provides a forum for academic and industrial scientists to discuss the latest developments in fermentation technology.

Key Points: 
  • RAFT provides a forum for academic and industrial scientists to discuss the latest developments in fermentation technology.
  • NanoAbs are monoclonal antibody (mAbs) 'bio-betters' in terms of cost, heat and shear force stability, high target affinity, and potential convenience to patients.
  • BiondVax's lead NanoAb candidate, for treatment of COVID-19, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies.
  • BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

Inscripta® Appoints Kristala Prather, PhD to its Board of Directors

Retrieved on: 
Wednesday, January 5, 2022

Inscripta, Inc., The Digital Genome Engineering Company, today announced that it has appointed Kristala Prather , PhD, to serve on its Board of Directors.

Key Points: 
  • Inscripta, Inc., The Digital Genome Engineering Company, today announced that it has appointed Kristala Prather , PhD, to serve on its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20220105005342/en/
    Inscripta, Inc., The Digital Genome Engineering Company, today announced that it has appointed Kristala Prather, PhD, to serve on its Board of Directors.
  • Dr. Prather is currently the Arthur D. Little Professor and Executive Officer of the Department of Chemical Engineering at MIT.
  • Inscripta supports its customers around the world from facilities in Boulder, Colo.; San Diego and Pleasanton, Calif.; and Copenhagen, Denmark.

Worldwide Pharmaceutical Analytical Testing Industry to 2026 - Increasing Number of Clinical Trials is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 25, 2021

The stability testing is done on the basis of five parameters : Chemical, physical, microbiological, therapeutic and toxicity.

Key Points: 
  • The stability testing is done on the basis of five parameters : Chemical, physical, microbiological, therapeutic and toxicity.
  • According to the study published by Journal of Industrial Microbiology & Biotechnology, almost 300 biopharmaceuticals have been patented in the last three decaded.
  • North America is expected to be a dominant region in the Pharmaceutical Analytical Testing market owing to increasing number of R&D activities and investments on it.
  • Thus, the increasing number of clinical trials and number of approved drugs is expected to boost up the demand of pharmaceutical analytical testing market growth in the North America Region.

Global GMP Testing Service Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 30, 2021

This demands more quality and safety management of products, which is expected to increase GMP testing services.

Key Points: 
  • This demands more quality and safety management of products, which is expected to increase GMP testing services.
  • Thus, the pharmaceutical and biopharmaceutical companies segment is expected to positively impact the GMP testing services market growth.
  • The number of increasing drug manufacturing plants is expected to drive the GMP testing services market growth.
  • Hence, these factors demand developing new drugs and are expected to boost the demand for GMP testing services market growth.

Industrial Microbiology Market - Growth, Trends, and Forecast (2019 - 2024)

Retrieved on: 
Wednesday, June 26, 2019

- In addition, the traditional R&D in the biopharmaceutical industry is witnessing an upsurge, due to drug development research, which is helping in the augmentation of the industrial microbiology market.

Key Points: 
  • - In addition, the traditional R&D in the biopharmaceutical industry is witnessing an upsurge, due to drug development research, which is helping in the augmentation of the industrial microbiology market.
  • - Increased demand for nutraceuticals and other fermented products further drives the importance of industrial application of microbiology on a large scale.
  • - However, in the market, there are several conflicts observed regarding the usage of genetically modified organisms in food sources, which are expected to restrict the growth of the industrial microbiology market.
  • All these factors have increased the use of microbes in fermentation, and thus, helped the growth of the microbiology market.